Advanced Functional Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Май 5, 2025
Abstract
Antigen‐presenting
cells
(APCs),
particularly
dendritic
(DCs),
play
key
roles
in
activating
T
for
enhanced
immune
response
cancer
immunotherapy.
In
progression,
an
immunosuppressive
tumor
microenvironment
(TME)
is
gradually
developed,
shielding
from
surveillance.
One
of
the
defects
created
by
TME
presence
dysfunctional
DCs,
which
triggers
failures
antigen
recognition,
processing,
and
presentation
to
cells,
inducing
impairment
anti‐tumor
responses.
The
demand
ex
vivo
cell
activation
expansion
replacement
autologous
DCs
imperative
adoptive
therapy
(ACT)
due
limited
availability
laborious
isolation
natural
DCs.
Therefore,
fabrication
artificial
APCs
(aAPCs)
mimicking
function
holds
promise
immunotherapy,
especially
ACT.
This
review
concentrates
on
design
aAPCs
using
principles
signaling
immunological
synapse:
receptor
(TCR)‐specific
(signal
1),
co‐stimulatory
signal
2),
cytokine‐mediated
3).
Particularly,
customization
size,
shape,
stiffness,
density,
mobility
ligands,
as
well
dimension
engagers
optimization
aAPCs,
also
discussed.
Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Март 20, 2024
Recent
research
in
artificial
cell
production
holds
promise
for
the
development
of
delivery
agents
with
therapeutic
effects
akin
to
real
cells.
To
succeed
these
applications,
systems
need
survive
circulatory
conditions.
In
this
review
we
present
strategies
that,
inspired
by
endurance
red
blood
cells,
have
enhanced
viability
large,
cell-like
vehicles
vivo
use,
particularly
focusing
on
giant
unilamellar
vesicles.
Insights
from
cells
can
guide
modifications
that
could
transform
platforms
into
advanced
drug
vehicles,
showcasing
biomimicry's
potential
shaping
future
applications.
Advanced Materials,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 10, 2025
Abstract
Cancer
immunotherapy,
which
leverages
immune
system
components
to
treat
malignancies,
has
emerged
as
a
cornerstone
of
contemporary
therapeutic
strategies.
Yet,
critical
concerns
about
the
efficacy
and
safety
cancer
immunotherapies
remain
formidable.
Nanotechnology,
especially
polymeric
nanoparticles
(PNPs),
offers
unparalleled
flexibility
in
manipulation‐from
chemical
composition
physical
properties
precision
control
nanoassemblies.
PNPs
provide
an
optimal
platform
amplify
potency
minimize
systematic
toxicity
broad
spectrum
immunotherapeutic
modalities.
In
this
comprehensive
review,
basics
polymer
chemistry,
state‐of‐the‐art
designs
from
physicochemical
standpoint
for
encompassing
vaccines,
situ
vaccination,
adoptive
T‐cell
therapies,
tumor‐infiltrating
cell‐targeted
antibodies,
cytokine
therapies
are
delineated.
Each
immunotherapy
necessitates
distinctively
tailored
design
strategies
nanoplatforms.
The
extensive
applications
PNPs,
investigation
their
mechanisms
action
enhanced
particularly
focused
on.
profiles
clinical
research
progress
discussed.
Additionally,
forthcoming
developments
emergent
trends
nano‐immunotherapeutics
poised
transform
treatment
paradigms
into
clinics
explored.
ACS Nano,
Год журнала:
2023,
Номер
17(16), С. 15918 - 15930
Опубликована: Авг. 11, 2023
Natural
killer
(NK)
cell
therapies
have
emerged
as
a
potential
therapeutic
approach
to
various
cancers.
Their
efficacy,
however,
is
limited
by
their
low
persistence
and
anergy.
Current
approaches
sustain
NK
in
vivo
include
genetic
modification,
activation
via
pretreatment,
or
coadministration
of
supporting
cytokines
antibodies.
Such
exhibit
efficacy
vivo,
part
due
the
reversal
effect
within
immunosuppressive
tumor
microenvironment
off-target
toxicity.
Here,
we
report
material-based
address
this
challenge.
Specifically,
describe
use
polymeric
micropatches
platform
for
sustained,
targeted
cells,
an
referred
microparticles
engagers
(MACE).
Poly(lactide-co-glycolic)
acid
(PLGA)
micropatches,
4-8
μm
diameter
surface-modified
with
receptor
targeting
antibodies,
exhibited
strong
adhesion
cells
induced
without
need
coadministered
cytokines.
The
MACE
was
greater
than
that
nanoparticles,
attesting
crucial
role
geometry
cells.
MACE-bound
remained
viable
trans-endothelial
migration
antitumor
activity
vitro.
activated
T
macrophages,
dendritic
Adoptive
transfer
NK-MACE
also
demonstrated
superior
mouse
melanoma
lung
metastasis
model
compared
unmodified
Overall,
offers
simple,
scalable,
effective
way
activating
represents
attractive
improve
therapy.
ACS Nano,
Год журнала:
2024,
Номер
18(12), С. 8571 - 8599
Опубликована: Март 14, 2024
T
cell-based
adoptive
cell
therapy
(ACT)
has
emerged
as
a
promising
treatment
for
various
diseases,
particularly
cancers.
Unlike
other
immunotherapy
modalities,
ACT
involves
directly
transferring
engineered
cells
into
patients
to
eradicate
diseased
cells;
hence,
it
necessitates
methods
effectively
activating
and
expanding
in
vitro.
Artificial
antigen-presenting
(aAPCs)
have
been
widely
developed
based
on
biomaterials,
micro-
nanoparticles,
functionalized
with
stimulatory
antibodies
closely
mimic
the
natural
cell–APC
interactions.
Due
their
vast
clinical
utility,
aAPCs
employed
an
off-the-shelf
technology
activation
FDA-approved
ACTs,
development
of
is
constantly
advancing
emergence
more
sophisticated
designs
additional
functionalities.
Here,
we
review
recent
advancements
particle-based
ACTs.
Following
brief
introduction,
first
describe
manufacturing
processes
products.
Next,
design
synthetic
strategies
nanoparticle-based
are
discussed
separately
emphasize
features,
advantages,
limitations.
Then,
impact
parameters
aAPCs,
such
size,
shape,
ligand
density/mobility,
stiffness,
functionality
biomedical
performance
explored
provide
deeper
insights
concepts
principles
efficient
safer
aAPCs.
The
concludes
by
discussing
current
challenges
proposing
future
perspectives
advanced
Nature Nanotechnology,
Год журнала:
2024,
Номер
19(11), С. 1735 - 1744
Опубликована: Июль 31, 2024
Abstract
Regulating
innate
immunity
is
an
emerging
approach
to
improve
cancer
immunotherapy.
Such
regulation
requires
engaging
myeloid
cells
by
delivering
immunomodulatory
compounds
hematopoietic
organs,
including
the
spleen.
Here
we
present
a
polymersome-based
nanocarrier
with
splenic
avidity
and
propensity
for
red
pulp
cell
uptake.
We
characterized
in
vivo
behaviour
of
four
chemically
identical
yet
topologically
different
polymersomes
positron
emission
tomography
imaging
innovative
flow
mass
cytometry
techniques.
Upon
intravenous
administration,
relatively
large
spherical
accumulated
rapidly
spleen
efficiently
targeted
pulp.
When
loaded
β-glucan,
intravenously
administered
significantly
reduced
tumour
growth
mouse
melanoma
model.
initiated
our
nanotherapeutic’s
clinical
translation
biodistribution
study
non-human
primates,
which
revealed
that
platform’s
preserved
across
species.
